Slight Q1 beat with 2025 guidance remaining unchanged
07/05/25 -"DiaSorin’s Q1 results marginally surpassed market expectations, demonstrating good performance across all segments. Profitability improved and management reaffirmed the 2025 guidance. Overall, ..."
Pages
63
Language
English
Published on
07/05/25
You may also be interested by these reports :
09/05/25
Sonova’s full-year results slightly exceeded market expectations, with robust growth across both segments. The promising FY2025-26 outlook was well ...
08/05/25
Qiagen commenced 2025 positively, with robust performance in Diagnostic Solutions and PCR/Nucleic Acid Amplification, although this was partially ...
08/05/25
Demant’s Q1 results met market expectations. Growth in Hearing Care was counterbalanced by weakness in Hearing Aids. Meanwhile, Diagnostics remained ...
07/05/25
DiaSorin’s Q1 results marginally surpassed market expectations, demonstrating good performance across all segments. Profitability improved and ...